image

REPORT SCOPE & OVERVIEW

The Antiepileptic Drugs Market size was estimated USD 17.4 billion in 2022 and is expected to reach USD 24.7 billion by 2030 at a CAGR of 4.5% during the forecast period of 2023-2030.

The antiepileptic medication, commonly known as an anti-seizure medication, was created for the asymptomatic and idiopathic treatment of epilepsy and seizures. Antiepileptic medications can also be used to treat neuropathic pain. Therapeutic Drug Monitoring is commonly used to optimise epilepsy therapy. The increasing prevalence of neurological disorders and advancements in medication modification are the primary factors driving market expansion. Furthermore, changing lifestyles, alcoholism, an increasing geriatric population, and active government support and investment will boost total market demand for Antiepileptic Drugs during the projection period of 2022–2030. Antiepileptic medications (AEDs) are anticonvulsants or antiseizure medicines that are used to treat the symptoms of epileptic seizures. Epileptic seizures are characterised by repeated occurrences and are caused by incorrect signals given to the brain by nerve cells. Antiepileptic medications also function as mood stabilisers and are used to treat bipolar disorders and neuropathic pain. The antiepileptics industry has been notably pushed by new medicine approvals in recent years. However, the recent patent expiration of big brands such as Lamictal is projected to stymie market expansion. Some of the prominent players in the worldwide antiepileptic medicine market are GlaxoSmithKline, Johnson & Johnson, Sanofi, Pfizer, Novartis, Abbott, Sunovion Pharmaceuticals, and Cephalon.

Antiepileptic Drugs Market Revenue Analysis

The First-generation class of antiepileptics, which includes phenytoin, carbamazepine, oxycarbazepine, and valproate, dominates the entire antiepileptics market. Because of their tolerability and effectiveness, the second-generation medicines zonisamide, levetiracetam, and lacosamide are gaining popularity. Geographically, the worldwide antiepileptic medicines market is divided into North America, Europe, Asia-Pacific, and Latin America and the Caribbean (LAMEA). Because of considerable R&D efforts and the existence of authorised second-generation antiepileptics, North America and Europe dominate the worldwide market.

MARKET DYNAMICS

DRIVERS

  • Epilepsy is becoming more common, and the senior population is growing.

  • Drug development advances, as well as increased awareness and diagnosis.

RESTRAIN

  • Side effects and safety concerns with Patent expirations, Regulatory issues.

Drowsiness, dizziness, cognitive impairment, and behavioural changes are all possible side effects of antiepileptic medications. Concerns about the safety of these medications may restrict their use and have an influence on market growth.
Several important antiepileptic medications have lost or are about to lose patent protection, resulting in increasing generic competition. For branded pharmaceuticals, this can lead to price erosion and revenue loss. Stringent regulations and approval processes for novel antiepileptic medications might cause pharmaceutical companies to postpone market entry and raise development expenses.

OPPORTUNITY

  • Emerging markets that are yet to be explored Medicine that is tailored to the individual's Technological progress.

CHALLENGES

  • Adherence and compliance issues, generic competition Ineffectiveness and tolerability.

Branded medications may experience pricing challenges and market share erosion when generic copies of antiepileptic treatments become accessible. In the treatment of epilepsy, non-adherence to drug regimens is a serious obstacle. Inadequate seizure control and treatment failure can come from poor compliance. Despite advances, certain individuals may not react well to currently available antiepileptic medicines or may have major side effects, prompting the development of more effective and well-tolerated alternatives.

IMPACT OF RUSSIAN UKRAINE WAR

Healthcare infrastructure is under stress. The war can put a burden on Ukraine's healthcare infrastructure, particularly in conflict-affected areas. The emphasis and resources may be shifted to emergency care and the treatment of war-related injuries, thereby compromising the supply and accessibility of antiepileptic medications. Instability in the economy Both Russia and Ukraine have experienced economic turmoil as a result of the conflict. Individual purchasing power, healthcare budgets, and total healthcare expenditures can all be impacted by this insecurity. It may reduce the price and accessibility of antiepileptic medications, thereby influencing market demand. War and conflict scenarios can contribute to increased stress, trauma, and injuries, which can lead to an increase in the occurrence of epilepsy. This might lead to an increase in the need for antiepileptic medications.

IMPACT OF ONGOING RECESSION

In economic downturns, generic substitution frequently leads to an increased desire for cost-cutting measures. In the case of antiepileptic pharmaceuticals, this may result in a greater demand for generic alternatives rather than branded treatments. Generic replacement may cause branded medicine prices to fall, reducing pharmaceutical firms' income. Recessions may put pressure on healthcare infrastructure as governments and healthcare providers confront financial limitations. This strain may impair the ability to successfully diagnose and treat epilepsy, thereby impacting the prescription and use of antiepileptic medicines.

KEY SEGMENTS

By Drug Generation

  • First Generation

  • Second Generation

  • Third Generation

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Drug Store

Antiepileptic Drugs Market Segmentation Analysis

REGIONAL COVERAGE

North America

  • US

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

REGIONAL ANALYSES

The market for antiepileptic medications is examined in North America, Europe, Asia-Pacific, and Latin America. North America accounted for a significant portion of the epilepsy medications market in 2022 and is likely to retain its dominance throughout the forecast period. The presence of numerous significant companies, such as Novartis AG and Abbott Laboratories, as well as the increasing adoption of epilepsy medications in this area, fuel market expansion.

During the projection period, Asia-Pacific is predicted to grow at the fastest rate. The presence of pharmaceutical businesses in the area, as well as the development of the buying power of populous nations like China and India, are driving market expansion in this region. Furthermore, rising healthcare expenditures and increased knowledge regarding early diagnosis and treatment are driving market expansion in this area. Furthermore, the Asia-Pacific area has the greatest medication supply and the largest pharmaceutical sector, with an abundance of raw materials that producers of antiepileptic drugs may easily acquire. This, in turn, increases the growth expectation for antiepileptic medications.

Key Players

The Major Key Players are Merck KGaA., Eisai Co., Ltd., AstraZeneca., Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Sanofi, GW Pharmaceutica Plc, and others.

Eisai Co., Ltd-Company Financial Analysis

RECENT DEVELOPMENT

Ovid Therapeutics

In January 2022, Ovid Therapeutics teamed with AstraZeneca to get exclusive access to a library of early-stage small molecules that target the KCC2 transporter, including the OV350-leading candidate.

Dr. Reddy Laboratories Ltd.

In January 2020, Dr. Reddy Laboratories Ltd. announced a distribution and co-promotion deal for Briviact in India with UCB S.A. Briviact has been licenced for the treatment of partial-onset seizures in individuals aged 16 and up.

Antiepileptic Drugs Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 17.4 Bn
Market Size by 2030  US$ 24.7 Bn
CAGR   CAGR of 4.5% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Drug Generation (First Generation, Second Generation, Third Generation)
• By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Store)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)
Company Profiles Merck KGaA., Eisai Co., Ltd., AstraZeneca., Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Sanofi, GW Pharmaceutica Plc
Key Drivers • Epilepsy is becoming more common, and the senior population is growing.
• Drug development advances, as well as increased awareness and diagnosis.
Market Restraints • Side effects and safety concerns with Patent expirations, Regulatory issues.

 

Frequently Asked Questions

Ans: The CAGR Growth rate of Antiepileptic Drugs Market is approx. CAGR 4.5% over the forecast.

Ans: The projected size of Antiepileptic Drugs Market was estimated USD 17.4 billion in 2022 and is expected to reach USD 24.7 billion by 2030  

Ans: The major key players are Merck KGaA., Eisai Co., Ltd., AstraZeneca., Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Sanofi, GW Pharmaceutica Plc, and others.

Ans: North America is the key region with the greatest market share.

Ans: Yes, you can ask for the customization as per your business requirement.

TABLE OF CONTENT

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 Impact of the Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Antiepileptic Drugs Market Segmentation, By Drug Generation
8.1 First Generation
8.2 Second Generation
8.3 Third Generation

9. Antiepileptic Drugs Market Segmentation, By Distribution Channel
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
9.4 Drug Store

10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Antiepileptic Drugs Market, by Country
10.2.2North America Antiepileptic Drugs Market, By Drug Generation
10.2.3 North America Antiepileptic Drugs Market, By Distribution Channel
10.2.4 USA
10.2.4.1 USA Antiepileptic Drugs Market, By Drug Generation
10.2.4.2 USA Antiepileptic Drugs Market, By Distribution Channel
10.2.5 Canada
10.2.5.1 Canada Antiepileptic Drugs Market, By Drug Generation
10.2.5.2 Canada Antiepileptic Drugs Market, By Distribution Channel
10.2.6 Mexico
10.2.6.1 Mexico Antiepileptic Drugs Market By Drug Generation
10.2.6.2 Mexico Antiepileptic Drugs Market By Distribution Channel
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Eastern Europe Antiepileptic Drugs Market by Country
10.3.1.2 Eastern Europe Antiepileptic Drugs Market By Drug Generation
10.3.1.3 Eastern Europe Antiepileptic Drugs Market By Distribution Channel
10.3.1.4 Poland
10.3.1.4.1 Poland Antiepileptic Drugs Market By Drug Generation
10.3.1.4.2 Poland Albumin By Distribution Channel
10.3.1.5 Romania
10.3.1.5.1 Romania Antiepileptic Drugs Market By Drug Generation
10.3.1.5.2 Romania Antiepileptic Drugs Market By Distribution Channel
10.3.1.6 Hungary
10.3.1.6.1 Hungary Antiepileptic Drugs Market By Drug Generation
10.3.1.6.2 Hungary Antiepileptic Drugs Market By Distribution Channel
10.3.1.7 Turkey
10.3.1.7.1 Turkey Antiepileptic Drugs Market By Drug Generation
10.3.1.7.2 Turkey Antiepileptic Drugs Market By Distribution Channel
10.3.1.8 Rest of Eastern Europe
10.3.1.8.1 Rest of Eastern Europe Antiepileptic Drugs Market By Drug Generation
10.3.1.8.2 Rest of Eastern Europe Antiepileptic Drugs Market By Distribution Channel
10.3.2 Western Europe
10.3.2.1 Western Europe Antiepileptic Drugs Market by Country
10.3.2.2 Western Europe Antiepileptic Drugs Market By Drug Generation
10.3.2.3 Western Europe Antiepileptic Drugs Market By Distribution Channel
10.3.2.4 Germany
10.3.2.4.1 Germany Antiepileptic Drugs Market By Drug Generation
10.3.2.4.2 Germany Antiepileptic Drugs Market By Distribution Channel
10.3.2.5 France
10.3.2.5.1 France Antiepileptic Drugs Market By Drug Generation
10.3.2.5.2 France Antiepileptic Drugs Market By Distribution Channel
10.3.2.6 UK
10.3.2.6.1 UK Antiepileptic Drugs Market By Drug Generation
10.3.2.6.2 UK Antiepileptic Drugs Market By Distribution Channel
10.3.2.7 Italy
10.3.2.7.1 Italy Antiepileptic Drugs Market By Drug Generation
10.3.2.7.2 Italy Antiepileptic Drugs Market By Distribution Channel
10.3.2.8 Spain
10.3.2.8.1 Spain Antiepileptic Drugs Market By Drug Generation
10.3.2.8.2 Spain Antiepileptic Drugs Market By Distribution Channel
10.3.2.9 Netherlands
10.3.2.9.1 Netherlands Antiepileptic Drugs Market By Drug Generation
10.3.2.9.2 Netherlands Antiepileptic Drugs Market By Distribution Channel
10.3.2.10 Switzerland
10.3.2.10.1 Switzerland Antiepileptic Drugs Market By Drug Generation
10.3.2.10.2 Switzerland Antiepileptic Drugs Market By Distribution Channel
10.3.2.11 Austria
10.3.2.11.1 Austria Antiepileptic Drugs Market By Drug Generation
10.3.2.11.2 Austria Antiepileptic Drugs Market By Distribution Channel
10.3.2.12 Rest of Western Europe
10.3.2.12.1 Rest of Western Europe Antiepileptic Drugs Market By Drug Generation
10.3.2.12.2 Rest of Western Europe Antiepileptic Drugs Market By Distribution Channel
10.4 Asia-Pacific
10.4.1 Asia Pacific Antiepileptic Drugs Market by Country
10.4.2 Asia Pacific Antiepileptic Drugs Market By Drug Generation
10.4.3 Asia Pacific Antiepileptic Drugs Market By Distribution Channel
10.4.4 China
10.4.4.1 China Antiepileptic Drugs Market By Drug Generation
10.4.4.2 China Antiepileptic Drugs Market By Distribution Channel
10.4.5 India
10.4.5.1 India Antiepileptic Drugs Market By Drug Generation
10.4.5.2 India Antiepileptic Drugs Market By Distribution Channel
10.4.6 Japan
10.4.6.1 Japan Antiepileptic Drugs Market By Drug Generation
10.4.6.2 Japan Antiepileptic Drugs Market By Distribution Channel
10.4.7 South Korea
10.4.7.1 South Korea Antiepileptic Drugs Market By Drug Generation
10.4.7.2 South Korea Antiepileptic Drugs Market By Distribution Channel
10.4.8 Vietnam
10.4.8.1 Vietnam Antiepileptic Drugs Market By Drug Generation
10.4.8.2 Vietnam Antiepileptic Drugs Market By Distribution Channel
10.4.9 Singapore
10.4.9.1 Singapore Antiepileptic Drugs Market By Drug Generation
10.4.9.2 Singapore Antiepileptic Drugs Market By Distribution Channel
10.4.10 Australia
10.4.10.1 Australia Antiepileptic Drugs Market By Drug Generation
10.4.10.2 Australia Antiepileptic Drugs Market By Distribution Channel
10.4.11 Rest of Asia-Pacific
10.4.11.1 Rest of Asia-Pacific Antiepileptic Drugs Market By Drug Generation
10.4.11.2 Rest of Asia-Pacific Antiepileptic Drugs Market By Distribution Channel
10.5 Middle East & Africa
10.5.1 Middle East
10.5.1.1 Middle East Antiepileptic Drugs Market by Country
10.5.1.2 Middle East Antiepileptic Drugs Market By Drug Generation
10.5.1.3 Middle East Antiepileptic Drugs Market By Distribution Channel
10.5.1.4 UAE
10.5.1.4.1 UAE Antiepileptic Drugs Market By Drug Generation
10.5.1.4.2 UAE Antiepileptic Drugs Market By Distribution Channel
10.5.1.5 Egypt
10.5.1.5.1 Egypt Antiepileptic Drugs Market By Drug Generation
10.5.1.5.2 Egypt Antiepileptic Drugs Market By Distribution Channel
10.5.1.6 Saudi Arabia
10.5.1.6.1 Saudi Arabia Antiepileptic Drugs Market By Drug Generation
10.5.1.6.2 Saudi Arabia Antiepileptic Drugs Market By Distribution Channel
10.5.1.7 Qatar
10.5.1.7.1 Qatar Antiepileptic Drugs Market By Drug Generation
10.5.1.7.2 Qatar Antiepileptic Drugs Market By Distribution Channel
10.5.1.8 Rest of Middle East
10.5.1.8.1 Rest of Middle East Antiepileptic Drugs Market By Drug Generation
10.5.1.8.2 Rest of Middle East Antiepileptic Drugs Market By Distribution Channel
10.5.2 Africa
10.5.2.1 Africa Antiepileptic Drugs Market by Country
10.5.2.2 Africa Antiepileptic Drugs Market By Drug Generation
10.5.2.3 Africa Antiepileptic Drugs Market By Distribution Channel
10.5.2.4 Nigeria
10.5.2.4.1 Nigeria Antiepileptic Drugs Market By Drug Generation
10.5.2.4.2 Nigeria Antiepileptic Drugs Market By Distribution Channel
10.5.2.5 South Africa
10.5.2.5.1 South Africa Antiepileptic Drugs Market By Drug Generation
10.5.2.5.2 South Africa Antiepileptic Drugs Market By Distribution Channel
10.5.2.6 Rest of Africa
10.5.2.6.1 Rest of Africa Antiepileptic Drugs Market By Drug Generation
10.5.2.6.2 Rest of Africa Antiepileptic Drugs Market By Distribution Channel
10.6 Latin America
10.6.1 Latin America Antiepileptic Drugs Market by Country
10.6.2 Latin America Antiepileptic Drugs Market By Drug Generation
10.6.3 Latin America Antiepileptic Drugs Market By Distribution Channel
10.6.4 Brazil
10.6.4.1 Brazil Antiepileptic Drugs Market By Drug Generation
10.6.4.2 Brazil Africa Antiepileptic Drugs Market By Distribution Channel
10.6.5 Argentina
10.6.5.1 Argentina Antiepileptic Drugs Market By Drug Generation
10.6.5.2 Argentina Antiepileptic Drugs Market By Distribution Channel
10.6.6 Colombia
10.6.6.1 Colombia Antiepileptic Drugs Market By Drug Generation
10.6.6.2 Colombia Antiepileptic Drugs Market By Distribution Channel
10.6.7 Rest of Latin America
10.6.7.1 Rest of Latin America Antiepileptic Drugs Market By Drug Generation
10.6.7.2 Rest of Latin America Antiepileptic Drugs Market By Distribution Channel

11 Company Profile
11.1 Merck KGaA
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Product/Services Offered
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Eisai Co., Ltd.
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Product/Services Offered
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 AstraZeneca.
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Product/Services Offered
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Novartis AG.
11.4 Company Overview
11.4.2 Financials
11.4.3 Product/Services Offered
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Abbott.
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Product/Services Offered
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Product/Services Offered
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Pfizer Inc.
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Product/Services Offered
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 GlaxoSmithKline plc.
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Product/Services Offered
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Sanofi.
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 GW Pharmaceutica Plc.
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Product/Services Offered
11.10.4 SWOT Analysis
11.10.5 The SNS View

12. Competitive Landscape
12.1 Competitive Bench marking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions

13. USE Cases and Best Practices

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone